Matrix metalloproteinase inhibitors (MMPIs) are being developed for various forms of cancer, arthritis (osteoarthritis and rheumatoid arthritis), periodontal diseases, and ocular diseases. Laboratory and clinical studies have established that MMPIs are orally active and, apart from possible musculoskeletal side effects, well tolerated compared with many of the drugs with which they will have to compete (e.g., cytotoxics and corticosteroids). Assuming MMPIs prove efficacious in ongoing clinical trials, their advantages will support the widespread use of these drugs, mainly for treating cancer and arthritis.

( Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Emerging Matrix Metalloproteinase Inhibitors is a new study published by Decision Resources, Inc., that presents a thorough review of the roles of MMPs in biology and disease, placing a major emphasis on the development of MMPIs. This study is based on in-depth interviews with researchers active in MMPI development and presents their views regarding the key issues involved in the successful commercialization of these agents. The relative merits of each MMPI are analyzed with respect to their market potential, as well as their ability to compete with existing therapies. An assessment of the most prominent pharmaceutical companies with significant MMPI development programs is also presented.

We project that sales of MMPIs for six major cancers (breast, non-small- cell lung, small-cell lung, prostate, ovarian, and colorectal) will generate sales of nearly $900 million by 2009, assuming positive results in ongoing trials. The main factor that may limit future sales of MMPIs for cancer is the wealth of competing antiangiogenesis agents being developed, of which several appear promising.

In the arthritis market, MMPIs face different challenges, particularly musculoskeletal side effects. However, considerable progress has been made in this area, and we believe that the early-stage MMPIs with improved side-effect profiles will succeed in the clinic. Assuming use in only a small fraction of early-stage patients, we estimate sales of MMPIs for arthritis will reach $1.3 billion by 2009-an impressive return for companies willing to venture into this "high-risk" arena.

Emerging Matrix Metalloproteinase Inhibitors is part of Mosaic, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or sama@dresources.com (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@compuserve.com (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-487-3753,
sama@dresources.com

Decision Resources Study Examines Unmet Needs in the Treatment of Allergic and Inflammatory Skin Disorders

View Now